The millennial-skewed telehealth platform Hims & Hers (HIMS) announced Monday that it will start offering customers a generic version of liraglutide, an older GLP-1 weight loss drug, next year. The news comes as some patients still struggle to fill prescriptions of the most advanced branded GLP-1 treatments on the market like Zepbound,

Hims & Hers currently offers compounded GLP-1 weight-loss injections at $199 per month and weight management oral medication kits at $79 per month

Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a generic version of a Novo Nordisk diabetes and weight-loss drug as early as next year.

Telehealth company Hims & Hers said late Monday in an earnings update that it plans to launch a generic version of Novo Nordisk’s diabetes drug as soon as 2025. It reported strong quarterly earnings.